BioSpace News Archive

Lannett Company, Inc. announced that it has recently sold previously discontinued abbreviated new drug applications for approximately $3 million to a privately held pharmaceutical company.

NovaBay® Pharmaceuticals, Inc. announces that management will present a company overview at the LD Micro Main Event XV on Wednesday, October 26 at 8:00 a.m. Pacific time.

Amryt today announces that its unaudited financial results for the third quarter 2022 will be released on Thursday, November 3, 2022 at 0700 ET/1100 GMT.

Tonix Pharmaceuticals Holding Corp. will present at the ThinkEquity Conference on Wednesday, October 26, 2022, at 10:30 a.m. ET, and host investor meetings.

Gritstone bio, Inc. today announced that it will host a webinar on October 25, 2022 to present data from its CORAL program and discuss the application of its self-amplifying mRNA (samRNA) vaccine platform for infectious diseases.

Plus Therapeutics, Inc. presented data from two ongoing clinical trials evaluating the Company’s lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM) at the 35th Annual Congress of the European Association of Nuclear Medicine (EANM).

Orionis Biosciences, a life sciences company pioneering innovation of highly selective and tunable therapeutics for cancer and beyond, today announced it has completed a $55 million financing round and expanded its team, naming Robert Petit, Ph.D., as Senior Vice President, Early Clinical Development and Bihua Chen to the Orionis Board of Directors.

OcuTerra Therapeutics, Inc. today announced the publication of a paper titled “The Safety and Biological Activity of OTT166, a Novel Topical Selective Integrin Inhibitor for the Treatment of Diabetic Eye Disease: A Phase 1b Study” in Ophthalmic Surgery, Lasers and Imaging Retina (OSLI Retina).

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the database lock on October 18, 2022 for the pivotal Phase 3 VIITAL™ study of its investigational autologous, engineered cell therapy, EB-101, in patients with recessive dystrophic epidermolysis bullosa (RDEB).

NeuPath Health Inc. today announced updates to the Company’s Board of Directors that will continue to support the Company’s leadership team in executing the strategic growth plan.